Literature DB >> 20665695

L-arginine hydrochloride increases the solubility of folded and unfolded recombinant plasminogen activator rPA.

Alexander Tischer1, Hauke Lilie, Rainer Rudolph, Christian Lange.   

Abstract

L-arginine hydrochloride (L-ArgHCl) was found to be an effective enhancer for in vitro protein refolding more than two decades ago. A detailed understanding of the mechanism of action, by which L-ArgHCl as co-solvent is capable to effectively suppress protein aggregation, while protein stability is preserved, has remained elusive. Concepts for the effects of co-solvents, which have been established over the last decades, were found to be insufficient to completely explain the effects of L-ArgHCl on protein refolding. In this article, we present data, which clearly establish that L-ArgHCl acts on the equilibrium solubility of the native model protein recombinant plasminogen activator (rPA), while for S-carboxymethylated rPA (IAA-rPA) that served as a model protein for denatured protein states, equilibrium solubilities could not be obtained. Solid to solute free transfer energies for native rPA were lowered by up to 14 kJ mol(-1) under the tested conditions. This finding is in marked contrast to a previously proposed model in which L-ArgHCl acts as a neutral crowder which exclusively has an influence on the stability of the transition state of aggregation. The effects on the apparent solubility of IAA-rPA, as well as on the aggregation kinetics of all studied protein species, that were observed in the present work could tentatively be explained within the framework of a nucleation-aggregation scheme, in which L-ArgHCl exerts a strong effect on the pre-equilibria leading to formation of the aggregation seed.
Copyright © 2010 The Protein Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20665695      PMCID: PMC2975141          DOI: 10.1002/pro.465

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  37 in total

Review 1.  Inclusion bodies: formation and utilisation.

Authors:  Beatrix Fahnert; Hauke Lilie; Peter Neubauer
Journal:  Adv Biochem Eng Biotechnol       Date:  2004       Impact factor: 2.635

Review 2.  The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics.

Authors:  Wolfgang Fraunhofer; Gerhard Winter
Journal:  Eur J Pharm Biopharm       Date:  2004-09       Impact factor: 5.571

3.  Role of arginine in the stabilization of proteins against aggregation.

Authors:  Brian M Baynes; Daniel I C Wang; Bernhardt L Trout
Journal:  Biochemistry       Date:  2005-03-29       Impact factor: 3.162

Review 4.  Field-flow fractionation in bioanalysis: A review of recent trends.

Authors:  Barbara Roda; Andrea Zattoni; Pierluigi Reschiglian; Myeong Hee Moon; Mara Mirasoli; Elisa Michelini; Aldo Roda
Journal:  Anal Chim Acta       Date:  2009-01-18       Impact factor: 6.558

Review 5.  Refolding solubilized inclusion body proteins.

Authors:  Richard R Burgess
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

6.  Abnormal solubility behavior of beta-lactoglobulin: salting-in by glycine and NaCl.

Authors:  T Arakawa; S N Timasheff
Journal:  Biochemistry       Date:  1987-08-11       Impact factor: 3.162

7.  Properties of an asymmetrical flow field-flow fractionation channel having one permeable wall.

Authors:  K G Wahlund; J C Giddings
Journal:  Anal Chem       Date:  1987-05-01       Impact factor: 6.986

8.  Ionic liquids as refolding additives: N'-alkyl and N'-(omega-hydroxyalkyl) N-methylimidazolium chlorides.

Authors:  Christian Lange; Ganesh Patil; Rainer Rudolph
Journal:  Protein Sci       Date:  2005-10       Impact factor: 6.725

Review 9.  Biotechnology applications of amino acids in protein purification and formulations.

Authors:  T Arakawa; K Tsumoto; Y Kita; B Chang; D Ejima
Journal:  Amino Acids       Date:  2007-03-16       Impact factor: 3.520

10.  The stabilization of proteins by sucrose.

Authors:  J C Lee; S N Timasheff
Journal:  J Biol Chem       Date:  1981-07-25       Impact factor: 5.157

View more
  9 in total

1.  Overproduction and biophysical characterization of human HSP70 proteins.

Authors:  Rebba C Boswell-Casteel; Jennifer M Johnson; Kelli D Duggan; Yuko Tsutsui; Franklin A Hays
Journal:  Protein Expr Purif       Date:  2014-09-27       Impact factor: 1.650

2.  Human Granulocyte-Macrophage Colony-Stimulating Factor Fused to Elastin-Like Polypeptides Assembles Biologically-Active Nanoparticles.

Authors:  Mincheol Park; Vijaya P Vaikari; Jugal P Dhandhukia; Houda Alachkar; J Andrew MacKay
Journal:  Bioconjug Chem       Date:  2020-05-05       Impact factor: 4.774

3.  Revisit PEG-Induced Precipitation Assay for Protein Solubility Assessment of Monoclonal Antibody Formulations.

Authors:  Martha J Scannell; Matthew W Hyatt; Ivan L Budyak; Mahlet A Woldeyes; Ying Wang
Journal:  Pharm Res       Date:  2021-10-13       Impact factor: 4.200

4.  Use of protein folding reagents.

Authors:  P T Wingfield
Journal:  Curr Protoc Protein Sci       Date:  2001-05

5.  A simplified method for the efficient refolding and purification of recombinant human GM-CSF.

Authors:  Christy A Thomson; Melanie Olson; Linda M Jackson; John W Schrader
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

6.  Refolded scFv antibody fragment against myoglobin shows rapid reaction kinetics.

Authors:  Hyung-Nam Song; Jun-Hyuck Jang; Young-Wan Kim; Dong-Hyung Kim; Sung-Goo Park; Myung Kyu Lee; Se-Hwan Paek; Eui-Jeon Woo
Journal:  Int J Mol Sci       Date:  2014-12-18       Impact factor: 5.923

7.  Improved Production and Biophysical Analysis of Recombinant Silicatein-α.

Authors:  Emily I Sparkes; Rachel A Kettles; Chisom S Egedeuzu; Natalie L Stephenson; Stephanie A Caslin; S Yasin Tabatabaei Dakhili; Lu Shin Wong
Journal:  Biomolecules       Date:  2020-08-20

8.  Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion.

Authors:  Camille Le Gall; Anna Cammarata; Lukas de Haas; Iván Ramos-Tomillero; Jorge Cuenca-Escalona; Kayleigh Schouren; Zacharias Wijfjes; Anouk M D Becker; Johanna Bödder; Yusuf Dölen; I Jolanda M de Vries; Carl G Figdor; Georgina Flórez-Grau; Martijn Verdoes
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 12.469

Review 9.  The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation.

Authors:  Jieliang Wang; Ying Peng; Haiyue Xu; Zhengrong Cui; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2020-08-05       Impact factor: 3.246

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.